Welcome to our dedicated page for THC FARMACEUTICALS news (Ticker: CBDG), a resource for investors and traders seeking the latest updates and insights on THC FARMACEUTICALS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect THC FARMACEUTICALS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of THC FARMACEUTICALS's position in the market.
On June 28, 2021, CBDual Biotechnology Corp's parent company, THC Farmaceuticals, Inc (OTC: CBDG), announced the passing of its Chairman and CEO, Senator Mike Gravel. Known for his political activism, Gravel contributed significantly to cannabis legalization efforts. His departure raises concerns about leadership stability in CBDG, which specializes in CBD and THC-based products. The company also focuses on clinical trials for cannabis and psilocybin innovations. As CBDG navigates these changes, it faces challenges in maintaining market confidence and investor relations.
CBDual Biotechnology Corp (OTC: CBDG) announced a binding agreement to acquire a controlling stake in G.K. Manufacturing from Cannabis Sativa, Inc. (OTCQB: CBDS). This acquisition aims to boost CBD product production, leveraging G.K.'s capacity to manufacture up to 12 million units monthly in Anaheim, California. The deal enhances CBDG's market position by expanding its product range and entering the U.S. market with established brands like Ganja Juice. The global CBD market, valued at USD 20.3 billion in 2019, is projected to grow at a CAGR of 25.6% through 2027.
FAQ
What is the market cap of THC FARMACEUTICALS (CBDG)?
